Absci (ABSI) Free Cash Flow (2020 - 2026)
Absci (ABSI) posted Free Cash Flow of -$26.3 million for Q1 2026, up 9.43% sequentially from -$29.1 million in Q4 2025, and down 20.46% YoY from -$33.1 million in Q1 2025.
Analysis
Absci (ABSI) Free Cash Flow (2020 - 2026) Analysis & Trends
Absci has reported Free Cash Flow for 7 years, with the latest figure at -$26.3 million in Q1 2026.
- Quarterly Free Cash Flow fell 20.46% year-over-year to -$26.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$98.5 million (down 28.25% YoY) and the FY2025 annual result came in at -$94.0 million, down 29.15% from the prior year.
- Free Cash Flow advanced to -$26.3 million in Q1 2026 per ABSI's latest filing, from -$29.1 million in the prior quarter.
- Over five years, Free Cash Flow peaked at -$2.9 million in Q4 2022 and troughed at -$32.7 million in Q3 2022.
- A 5-year average of -$19.9 million and a median of -$20.2 million in 2023 frame the typical range for Free Cash Flow.
- The widest YoY moves for Free Cash Flow: up 78.02% in 2022, down 2586.51% in 2022.
- Over 5 years, Free Cash Flow stood at -$2.9 million in 2022, then plunged by 407.55% to -$14.9 million in 2023, then dropped by 15.91% to -$17.3 million in 2024, then sank by 68.13% to -$29.1 million in 2025, then grew by 9.43% to -$26.3 million in 2026.
- According to Business Quant data, Free Cash Flow over the past three periods registered -$26.3 million, -$29.1 million, and -$26.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -563.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -389.61 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 437.80 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 292.04 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 477.44 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Absci | 1.39 Bn | 1.19 Bn | - | -27.57 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -27.57 Mn |
| Mar 31, 2026 | -26.34 Mn |
| Dec 31, 2025 | -29.08 Mn |
| Sep 30, 2025 | -25.99 Mn |
| Jun 30, 2025 | -17.10 Mn |
| Mar 31, 2025 | -21.86 Mn |
| Dec 31, 2024 | -17.12 Mn |
| Sep 30, 2024 | -20.78 Mn |
| Jun 30, 2024 | -17.18 Mn |
| Mar 31, 2024 | -17.86 Mn |
| Dec 31, 2023 | -14.94 Mn |
| Sep 30, 2023 | -10.67 Mn |
| Jun 30, 2023 | -19.49 Mn |
| Mar 31, 2023 | -20.40 Mn |
| Dec 31, 2022 | -19.13 Mn |
| Sep 30, 2022 | -23.91 Mn |
| Jun 30, 2022 | -26.47 Mn |
| Mar 31, 2022 | -28.01 Mn |
| Dec 31, 2021 | -25.40 Mn |
| Sep 30, 2021 | -27.37 Mn |